When should people with Eczema / Atopic Dermatitis (AD) be offered systemic therapy?
New consensus framework to provide a structure for patients and caregivers to make a decision about systemic therapies Atopic dermatitis (AD), also known as atopic eczema, is a common, itchy and unpleasant condition. AD has significant well-established comorbidities (associated conditions) including food allergy, asthma and allergic rhinitis, in addition to newly-recognised comorbidities including those related […]
The U.S. Food and Drug Administration approves first biologic for treatment of eczema
On March 28th 2017, the U.S. Food and Drug Administration (FDA) approved a new drug called dupilumab (brand name: Dupixent) for the treatment of adults with moderate-to-severe atopic dermatitis (also known as atopic eczema) that is not adequately controlled with topical treatment, or for whom topical treatments are not appropriate. This new drug is administered […]
